TGFB1 and metabolic dysfunction-associated steatotic liver disease: No differences were detected between obese patients with or without NAFLD in the expression levels of DPT and TGFB1 in the liver (Figure 1E), while TGFB1 gene expression was significantly upregulated (p < 0.01) in obese patients with NAFLD in VAT (Figure 1F).